• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    GRAIL Appoints Sarah Krevans to Board of Directors

    10/21/24 4:01:00 PM ET
    $GRAL
    Medical Specialities
    Health Care
    Get the next $GRAL alert in real time by email

    MENLO PARK, Calif., Oct. 21, 2024 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced the appointment of Sarah Krevans to its Board of Directors, effective immediately. Ms. Krevans will also serve as a member of the Board's Audit Committee, Compensation Committee, and Nominating and Governance Committee. Following the appointment of Ms. Krevans, the Board will be composed of five directors, four of whom are independent.

    CEO Sutter Health

    Ms. Krevans served as president and CEO of Sutter Health, a Northern California based not-for-profit health system in one of the most diverse and innovative regions in the nation, from 2016 to 2022. She was responsible for Sutter Health's integrated network of 14,000 clinicians, 24 hospitals, outpatient services, research facilities, and home health and hospice care. Under her leadership, Ms. Krevans advanced clinical programs, innovation, and digital health to make healthcare more accessible for patients.

    "Sarah is a highly accomplished healthcare leader with extensive experience in a dynamic and diverse environment," said Bob Ragusa, CEO of GRAIL. "I am confident that her experience will bring immense value to GRAIL as we move toward establishing a new standard of care for multi-cancer early detection for patients."

    Previously, Ms. Krevans served as chief operating officer, and regional executive officer and president of the Sutter Health Sacramento Sierra Region. She also held executive roles at Kaiser Permanente and served as deputy director of Maine's Bureau of Medical Services and acting director of Medicaid, health planning and licensure programs. Ms. Krevans' experience as a board member includes serving on many not-for-profit boards and as Chair of the California Association of Hospitals. She currently serves on the board of the Acacium Group and is the incoming Chair of CaringBridge.

    Ms. Krevans earned master's degrees in business administration and in public health from the University of California, Berkeley, and a bachelor's degree from Boston University. She has been named as one of the "Top 25 Women Leaders" by Modern Healthcare and included on Modern Healthcare's list of the "100 Most Influential People in Healthcare."

    About GRAIL

    GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom.

    For more information, visit grail.com.

    GRAIL, Inc. is a healthcare company whose mission is to detect cancer early when it can be cured. (PRNewsfoto/GRAIL, Inc.)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/grail-appoints-sarah-krevans-to-board-of-directors-302282199.html

    SOURCE GRAIL, Inc.

    Get the next $GRAL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Q&A

    New
    • What recent leadership change happened at GRAIL, Inc.?

      GRAIL, Inc. appointed Sarah Krevans to its Board of Directors effective immediately, bringing the total number of directors to five, with four being independent.

    • What was Sarah Krevans' role before joining GRAIL?

      Sarah Krevans previously served as the president and CEO of Sutter Health from 2016 to 2022, overseeing a large healthcare network in Northern California.

    • What contributions did Sarah Krevans make in her previous positions?

      Ms. Krevans is known for her strong background in healthcare leadership, having advanced clinical programs and digital health initiatives during her tenure at Sutter Health.

    • What is the primary mission of GRAIL, Inc.?

      GRAIL focuses on early cancer detection by utilizing next-generation sequencing and advanced machine learning techniques to identify multiple cancer types.

    • What ambitions does GRAIL have following the appointment of Sarah Krevans?

      Under Ms. Krevans' leadership, GRAIL aims to establish a new standard for multi-cancer early detection, benefiting patients with innovative healthcare solutions.

    Recent Analyst Ratings for
    $GRAL

    DatePrice TargetRatingAnalyst
    4/21/2025$32.00Buy
    Canaccord Genuity
    11/27/2024$16.00Equal-Weight
    Morgan Stanley
    11/15/2024Peer Perform
    Wolfe Research
    10/17/2024Neutral
    Guggenheim
    More analyst ratings